These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26463243)

  • 1. Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile.
    Ganzetti G; Campanati A; Molinelli E; Offidani A
    Curr Drug Saf; 2016; 11(1):12-21. PubMed ID: 26463243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic Therapy in Psoriasis: Safety Profile.
    Campanati A; Ganzetti G; Giuliodori K; Molinelli E; Offidani A
    Curr Drug Saf; 2016; 11(1):4-11. PubMed ID: 26463245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hidradenitis suppurativa with biologic medications.
    Lee RA; Eisen DB
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile.
    Moroncini G; Albani L; Nobili L; Gabrielli A
    Curr Drug Saf; 2016; 11(1):44-6. PubMed ID: 26463247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile.
    Luchetti MM; Balloni A; Gabrielli A
    Curr Drug Saf; 2016; 11(1):22-34. PubMed ID: 26463246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in dermatology.
    Hong JJ; Hadeler EK; Mosca ML; Brownstone ND; Bhutani T; Liao WJ
    Dermatol Online J; 2021 Nov; 27(11):. PubMed ID: 35130397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
    Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics for chronic inflammatory skin diseases: an update for the clinician.
    Yao Y; Ravn Jørgensen AH; Thomsen SF
    J Dermatolog Treat; 2020 Mar; 31(2):108-130. PubMed ID: 30827126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients.
    Sand FL; Thomsen SF
    Dermatol Ther; 2015; 28(3):158-65. PubMed ID: 25731720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label dermatologic uses of IL-17 inhibitors.
    Wu KK; Dao H
    J Dermatolog Treat; 2022 Feb; 33(1):41-47. PubMed ID: 32116066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Practical Guide to Using Biologics in Pediatric Dermatology.
    George A; Lansang RP; Lansang P; Gooderham M
    J Cutan Med Surg; 2024; 28(1):59-67. PubMed ID: 38229411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No seroconversion in a retrospective study analyzing QuantiFERON TB-gold testing in pediatric psoriasis and hidradenitis suppurativa patients taking biologic therapy at an academic center in New York City.
    Katsiaunis A; Conway J; Lipner SR
    Pediatr Dermatol; 2024; 41(4):733-735. PubMed ID: 38413181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What’s news in dermatological therapy?].
    Guillot B
    Ann Dermatol Venereol; 2013 Nov; 140 Suppl 3():S293-302. PubMed ID: 24365501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What's New in Dermatological Therapy?].
    Bachelez H
    Ann Dermatol Venereol; 2015 Dec; 142 Suppl 3():S49-54. PubMed ID: 26792414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-psoriatic dermatologic uses of monoclonal antibody therapy.
    Sockolov ME; Alikhan A; Zargari O
    J Dermatolog Treat; 2009; 20(6):319-27. PubMed ID: 19954387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Navigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules.
    Costello C; Maarouf M; Shi V
    J Drugs Dermatol; 2018 Dec; 17(12):1330-1332. PubMed ID: 30586268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases.
    Machet L; Samimi M; Delage M; Paintaud G; Maruani A
    J Am Acad Dermatol; 2013 Oct; 69(4):649-50. PubMed ID: 24034373
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
    Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
    Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
    Patsatsi A; Kyriakou A
    Clin Dermatol; 2021; 39(1):52-55. PubMed ID: 33972053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.
    Zouboulis CC
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1015-26. PubMed ID: 27531618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.